The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Optimizing the Clinical Use of Vancomycin
Open accessAbstract
The increasing number of infections produced by beta-lactam–resistant Gram-positive bacteria and the morbidity secondary to these infections make it necessary to optimize the use of vancomycin. In 2009, the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists published specific guidelines about vancomycin dosage and monitoring. However, these guidelines have not been updated in the past 6 years. This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomycin dosing in special situations (obese people, burn patients, renal replacement therapy, among others). Vancomycin efficacy is linked to a correct dosage which should aim to reach an area under the curve (AUC)/MIC ratio of ≥400; serum trough levels of 15 to 20 mg/liter are considered a surrogate marker of an AUC/MIC ratio of ≥400 for a MIC of ≤1 mg/liter. For Staphylococcus aureus strains presenting with a MIC >1 mg/liter, an alternative agent should be considered. Vancomycin doses must be adjusted according to body weight and the plasma trough levels of the drug. Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especially for patients at high risk of renal impairment or unstable vancomycin clearance. In such cases, vancomycin plasma steady-state level and creatinine monitoring are strongly indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
The periodic health examination. Canadian Task Force on the Periodic Health Examination.
(1979) · PubMed · Cited by 671
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-13 · Cited by 392
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Wysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2460-2467.2001 · Cited by 385
Wang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01388-06 · Cited by 358
An overview of drug-induced acute kidney injury
Pannu, N., & Nadim, M. K. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318168e375 · Cited by 352
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
LaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-11 · Cited by 252
Vancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01708-10 · Cited by 226
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
Cataldo, M. A., Tacconelli, E., Grilli, E., Pea, F., & Petrosillo, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr442 · Cited by 204
The Periodic Health Examination: 1980
DELBANCO, T. L., & TAYLOR, W. C. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-251 · Cited by 179
Lodise, T. P., Drusano, G. L., Zasowski, E., Dihmess, A., Lazariu, V., Cosler, L., & McNutt, L.-A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu398 · Cited by 167
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Dosing of antibiotics in obesity
Janson, B., & Thursky, K. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328359a4c1 · Cited by 160
CUESTA, N. R., Martín‐Suárez, A., Pérez, M. P., Martín-González, F., & Gatta, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03679.x · Cited by 152
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 131
Jamal, J., Udy, A. A., Lipman, J., & Roberts, J. A. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000317 · Cited by 127
Pharmacodynamics: Relation to Antimicrobial Resistance
Rybak, M. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.04.001 · Cited by 120
Pea, F., Furlanut, M., Negri, C., Pavan, F., Crapis, M., Cristini, F., & Viale, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01149-08 · Cited by 118
Zelenitsky, S. A., Rubinstein, E., Ariano, R. E., Iacovides, H., Dodek, P., Mirzanejad, Y., & Kumar, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.015 · Cited by 116
Brown, J. E., Brown, K., & Forrest, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05609-11 · Cited by 116
Vancomycin-Associated Nephrotoxicity in the Critically Ill
Hanrahan, T. P., Harlow, G., HUTCHINSON, J. H., Dulhunty, J. M., Lipman, J., Whitehouse, T., & Roberts, J. A. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000514 · Cited by 111
Suzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 110
Kullar, R., Leonard, S. N., Davis, S. L., Delgado, G., Pogue, J. M., Wahby, K. A., Falcione, B. A., & Rybak, M. J. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.441 · Cited by 106
LaPlante, K. L., Leonard, S. N., Andes, D. R., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01046-07 · Cited by 106
Jung, Y., Song, K., Cho, J. E., Kim, H.-S., Kim, N., Kim, T. S., Choe, P. G., Chung, J., Park, W. B., Bang, J. H., et al. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.017 · Cited by 99
Grace, E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks066 · Cited by 95
Vancomycin enhancement of experimental tobramycin nephrotoxicity
Wood, C. A., Kohlhepp, S. J., Kohnen, P. W., Houghton, D. C., & Gilbert, D. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.1.20 · Cited by 86
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
Touw, D. J. (1998) · Pharmacy World & Science · doi:10.1023/a:1008634911114 · Cited by 81
Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus
Ruef, C. (2004) · Infection · doi:10.1007/s15010-004-4124-7 · Cited by 81
Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity
Hall, R. G., Payne, K. D., Bain, A. M., Rahman, A. P., Nguyen, S., Eaton, S. A., Busti, A. J., Vu, S. L., & Bedimo, R. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.046 · Cited by 71
Necessity of a loading dose when using vancomycin in critically ill patients
Wang, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.2.246 · Cited by 71
Vancomycin therapeutics and monitoring: a contemporary approach
Avent, M. L., Vaska, V. L., Rogers, B. A., Cheng, A. C., van Hal, S. J., Holmes, N. E., Howden, B. P., & Paterson, D. L. (2012) · Internal Medicine Journal · doi:10.1111/imj.12036 · Cited by 68
Truong, J. Q., Levkovich, B., & Padiglione, A. A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02459.x · Cited by 62
Rodríguez‐Baño, J., Millán, A. B., Domínguez, M. Á., Borraz, C., González, M. P., Almirante, B., Cercenado, E., Padilla, B., & Pujol, M. (2009) · Journal of Infection · doi:10.1016/j.jinf.2008.11.003 · Cited by 62
Prevention of vancomycin induced nephrotoxicity: a review of preclinical data
Elyasi, S., Khalili, H., Hatamkhani, S., & Dashti‐Khavidaki, S. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1406-3 · Cited by 59
A higher dose of vancomycin in continuous infusion is needed in critically ill patients
Jeurissen, A., Sluyts, I., & Rutsaert, R. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.09.004 · Cited by 57
Continuous intravenous administration of vancomycin in medical intensive care unit patients
Saugel, B., Nowack, M., Hapfelmeier, A., Umgelter, A., Schultheiß, C., Thies, P., Phillip, V., Eyer, F., Schmid, R. M., & Huber, W. (2012) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.02.003 · Cited by 56
Udy, A. A., Covajes, C., Taccone, F. S., Jacobs, F., Vincent, J., Lipman, J., & Roberts, J. A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.018 · Cited by 56
Performance of a vancomycin dosage regimen developed for obese patients
Reynolds, D. C., Waite, L. H., Alexander, D. P., & DeRyke, C. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110324 · Cited by 56
Hall, R. G., Hazlewood, K. A., Brouse, S. D., Giuliano, C. A., Haase, K. K., Frei, C. R., Forcade, N. A., Bell, T., Bedimo, R., & Álvarez, C. A. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-12 · Cited by 55
A Randomized Trial of Loading Vancomycin in the Emergency Department
Rosini, J. M., Laughner, J., Levine, B. J., Papas, M. A., Reinhardt, J. F., & Jasani, N. B. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556813 · Cited by 54
Harigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., & Tsuji, B. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01585-08 · Cited by 54
A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy
Beumier, M., Roberts, J. A., Kabtouri, H., Hites, M., COTTON, F. J., Wolff, F., Lipman, J., Jacobs, F., Vincent, J., & Taccone, F. S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt261 · Cited by 54
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients
Chaijamorn, W., Jitsurong, A., Wiwattanawongsa, K., Wanakamanee, U., & Dandecha, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.04.010 · Cited by 52
Spapen, H. D., van Doorn, K. J., Diltoer, M., Verbrugghe, W., Jacobs, R., Dobbeleir, N., Honoré, P. M., & Jorens, P. G. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-26 · Cited by 52
Akers, K. S., Cota, J. M., Chung, K. K., Renz, E. M., Mende, K., & Murray, C. K. (2012) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31825042fa · Cited by 47
Ampe, E., Delaere, B., Hecq, J., Tulkens, P. M., & Glupczynski, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.009 · Cited by 42
Pharmacokinetics of vancomycin in adult cystic fibrosis patients
Pleasants, R. A., Michalets, E. L., Williams, D. M., Samuelson, W. M., Rehm, J. R., & Knowles, M. R. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.1.186 · Cited by 37
Escobar, L., Andresen, M., Downey, P., Gai, M. N., Regueira, T., Bórquez, T., Lipman, J., & Roberts, J. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.03.009 · Cited by 35
Vandecasteele, S. J., Bacquer, D. D., & Vriese, A. S. D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir337 · Cited by 35
Optimizing initial vancomycin dosing in burn patients
Elligsen, M., Walker, S. A. N., Walker, S. E., & Simor, A. E. (2010) · Burns · doi:10.1016/j.burns.2010.06.005 · Cited by 30
Davies, S. W., Guidry, C. A., Petroze, R. T., Hranjec, T., & Sawyer, R. G. (2013) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3182a74b70 · Cited by 28
Petejová, N., Martínek, A., Zahalkova, J., Ďuricová, J., Brozmanová, H., Urbánek, K., Grundmann, M., Plášek, J., & Kacířová, I. (2012) · Biomedical Papers · doi:10.5507/bp.2012.092 · Cited by 28
Docobo-Pérez, F., López-Rojas, R., Domínguez-Herrera, J., Me, J.-M., Pichardo, C., Ibáñez-Martínez, J., & Pachón, J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks142 · Cited by 26
Self-citationNorton, K., Ingram, P. R., Heath, C. H., & Manning, L. A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt402 · Cited by 22
Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations
Wesner, A. R., Brackbill, M. L., Coyle, L. L., & Kidd, R. S. (2013) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2013/839456 · Cited by 20
Risk of Vancomycin-induced Nephrotoxicity in the Population With Chronic Kidney Disease
Panwar, B., Johnson, V. A., Patel, M., & Balkovetz, D. F. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318268023d · Cited by 17
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
Lubenko, I. Y., Strukova, E. N., Smirnova, M. V., Vostrov, S. N., Абрамович, П. Ю., Zinner, S. H., & Firsov, A. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn288 · Cited by 15
Zelenitsky, S. A., Alkurdi, N., Weber, Z., Ariano, R. E., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01472-10 · Cited by 13
Vancomycin Dosing Nomogram for Haemodialysis Patients
Jeremiah, C. J., Wills, C., Bayly, A., Perry, G. J., Davis, J. S., Tong, S. Y. C., & Currie, B. J. (2014) · Nephrology · doi:10.1111/nep.12270 · Cited by 10
Cited by
(2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003668 · Cited by 423
Developments in Glycopeptide Antibiotics
Blaskovich, M. A. T., Hansford, K. A., Butler, M. S., Jia, Z., Mark, A. E., & Cooper, M. A. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00258 · Cited by 265
Metadata
- Authors
- Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-05
- Volume
- 60
- Issue
- 5
- Pages
- 2601-2609
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2339844999
- Cited by
- 258
- References
- 76
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.